Oncocyte is at a pivotal stage in commercializing what we expect to be an industry-transforming organ transplant rejection monitoring test. We aim to deliver proven, more affordable, faster tests that ...

--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company ... cfDNA in detecting allograft rejection was consistent with its AlloSure® lab developed test.

Major discrepancies are seen with the use of noninvasive tests compared with liver biopsy in a posttransplant setting.

A large team of surgeons and organ transplant researchers ... which led to rejection of the lungs. The team also found that ...

BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization ...

Crossmatch tests of the prospective kidney ... antibodies may develop as a result of homograft rejection and may be detected especially after transplant nephrectomy. 7 On this basis, immediate ...

[Reuters] For the first time, a pig kidney has been transplanted into a human without triggering immediate rejection ... a heart transplant recipient. Those trials might test the approach as ...

Event: 24th Annual Needham Virtual Healthcare Conference Dates: April 7-10, 2025 Oncocyte Fireside Chat: April 7, 2025, 3:45 PM (ET) Location: Virtual For more information about Oncocyte and its ...